

IN THE CLAIMS:

1. (Currently Amended) A chemically synthesized double stranded ~~short interfering~~ nucleic acid (~~siNA~~) molecule comprising a sense strand and an antisense strand that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference, wherein:
 - a. each strand of said ~~siNA double stranded nucleic acid~~ molecule is about 1918 to about 2327 nucleotides in length;
 - b. ~~one-the antisense~~ strand of said ~~siNA double stranded nucleic acid~~ molecule comprises nucleotide sequence ~~having sufficient complementarity to said CHRM3 RNA for the siNA molecule to direct cleavage of the CHRM3 RNA via RNA interference that is complementary to a cholinergic receptor muscarinic 3 (CHRM3) nucleotide sequence comprising SEQ ID NO: 305; and the sense strand is complementary to the antisense strand;~~ and
 - c. ~~said siNA double stranded nucleic acid molecule does not require the presence of nucleotides having a 2' hydroxy group for mediating RNA interference~~comprises at least one chemically modified nucleotide in said sense strand and said antisense strand of said double stranded nucleic acid molecule.
2. (Canceled)
3. (Currently Amended) The ~~siNA double stranded nucleic acid~~ molecule of claim 1, wherein said ~~siNA double stranded nucleic acid~~ molecule comprises one or more ribonucleotides.
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)

8. (Canceled)
9. (Canceled)
10. (Currently Amended) The siNA double stranded nucleic acid molecule of claim claim 6 1, wherein said sense region strand is connected to the antisense region strand via a linker molecule.
11. (Currently Amended) The siNA double stranded nucleic acid molecule of claim 10, wherein said linker molecule is a polynucleotide linker.
12. (Currently Amended) The siNA double stranded nucleic acid molecule of claim 10, wherein said linker molecule is a non-nucleotide linker.
13. (Currently Amended) The siNA double stranded nucleic acid molecule of claim 6 1, wherein one or more pyrimidine nucleotides present in the sense region strand are 2'-O-methyl pyrimidine nucleotides.
14. (Currently Amended) The siNA double stranded nucleic acid molecule of claim 6 1, wherein one or more purine nucleotides present in the sense region strand are 2'-deoxy purine nucleotides.
15. (Currently Amended) The siNA double stranded nucleic acid molecule of claim 6 1, wherein one or more pyrimidine nucleotides present in the sense region strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides.
16. (Currently Amended) The siNA double stranded nucleic acid molecule of claim 9 1, wherein the fragment comprising said sense region strand includes a terminal cap moiety at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the fragment comprising said sense region strand.
17. (Currently Amended) The siNA double stranded nucleic acid molecule of claim 16, wherein said terminal cap moiety is an inverted deoxy abasic moiety.
18. (Currently Amended) The siNA double stranded nucleic acid molecule of claim 6 1, wherein one or more pyrimidine nucleotides of said present in the antisense region strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides

19. (Currently Amended) The siNA double stranded nucleic acid molecule of claim 6 1, wherein one or more purine nucleotides of said present in the antisense region strand are 2'-O-methyl purine nucleotides.
20. (Currently Amended) The siNA double stranded nucleic acid molecule of claim 6 1, wherein one or more purine nucleotides present in said the antisense region strand comprise are 2'-deoxy- purine nucleotides.
21. (Currently Amended) The siNA double stranded nucleic acid molecule of claim 18 1, wherein said the antisense region strand comprises a terminal phosphorothioate internucleotide linkage at the 3' end of said the antisense region strand.
22. (Canceled)
23. (Canceled)
24. (Canceled)
25. (Canceled)
26. (Canceled)
27. (Canceled)
28. (Canceled)
29. (Canceled)
30. (Currently Amended) The siNA double stranded nucleic acid molecule of claim 9 1, wherein the 5'-end of the fragment comprising said antisense region strand optionally includes a terminal phosphate group.
31. (Currently Amended) A pharmaceutical composition comprising the siNA double stranded nucleic acid molecule of claim 1 in an a pharmaceutically acceptable carrier or diluent.